“Targeting Cancer, Sparing Patients”
Scientific American
In this feature story, Jyoti S. Madhusoodanan takes a deep dive into the history and science of antibody-drug conjugates (ADCs), a new class of drugs that target a wide range of cancers. Scientists have pursued the dream of targeted cancer treatments for nearly a century, and ADCs mark a significant milestone in that quest. Madhusoodanan expertly tells an insightful story that balances science and clinical impact, taking readers on a tour of the science behind these drugs, researchers’ motivations and persistence in developing such therapies, and the deep joy doctors have felt to see their patients benefit from ADCs during clinical trials and beyond.
Read the Story